IN THE CLAIMS

Please amend claim s 1, 31, 26, 36, and 65 and add new claims 80-84 as follows:

1. (currently amended) A method for inhibiting cell growth or enhancing cell death comprising:

(a) providing to a cell a pharmaceutically acceptable formulation consisting essentially of (i) a photosensitive agent that is a photosensitive agent or (ii) a plurality of different photosensitive agent species, wherein at least one of the photosensitive agent species is a photooxidizing agent ~~to a cell~~;

(b) applying an electric pulse to the cell of a sufficient strength and duration to electroporate the cell with the ~~photooxidizing~~ photosensitive agent(s); and

(c) applying light of a photoactivating wavelength to the cell thereby activating the agent(s) and inhibiting cell growth or enhancing cell death.

2. (original) The method of claim 1, wherein multiple electric pulses are applied to the cell.

3. (original) The method of claim 1, wherein the electric pulse's amplitude is about 10 V/cm to about 6.0 kV/cm.

C1

4. (original) The method of claim 1, wherein the electric pulse's duration is about 0.1 to about 10 milliseconds.

5. (original) The method of claim 1, wherein the pulse is applied using at least two electrodes.

6-12. (canceled)

PAGE 4/13 * RCVD AT 1/8/2004 12:27:23 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/4 * DNIS:8729305 * CSID:18583509691 * DURATION (mm-ss):06-08

13. (original) The method of claim 1, wherein the light is applied prior to, simultaneously with, or following the electric pulse.

14. (original) The method of claim 1, wherein the light is applied by a laser.

15. (original) The method of claim 1, wherein the light is applied by a tungsten lamp.

16. (original) The method of claim 1, wherein the light is applied by a near ultraviolet lamp.

17. (original) The method of claim 1, wherein the light has a wavelength of about 300 to about 950 nm.

18. (original) The method of claim 1, wherein the amount of light applied is about 50 to about 1000J/cm^2.

19-22. (canceled)

23. (original) The method of claim 1, further comprising applying heat to the cell.

24. (currently amended) The method of claim 23, wherein the heat has a temperature of about 36°C to about 42°C ~~degrees~~.

25. (canceled)

26. (currently amended) The method of claim 1, wherein the photooxidizing agent is selected from the group consisting of thiopyronin, acridine orange, Zn-phthalocyanine-sulfonate, benzoporphyrin, protoporphyrin, ~~hematoporphyrin.~~ PHOTOFRIN I, PHOTOFRIN II, ANTRIN and porphycene.

Jan 06 04 05:27a Biotechnology Law Group 18583509691 p.4

PAGE 5/13 * RCVD AT 1/6/2004 12:27:23 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729303 * CSID:18583509891 * DURATION (mm-ss):08-08

27. (original) The method of claim 1, wherein the photooxidizing agent is a cytostatic agent.

28. (original) The method of claim 27, wherein the cytostatic agent is selected from the group consisting of daunomycin, adriamycin and actinomycin.

29. (original) The method of claim 1, further comprising providing a sensitizing agent.

30. (original) The method of claim 29, wherein the sensitizing agent is l aevuline acid.

31. (currently amended) The method of claim 1 ~~30~~, wherein the photooxidizing agent is protoporphyrin IX.

32. (original) The method of claim 1, wherein the method is performed in a subject.

33. (original) The method of claim 32, wherein the subject is a human.

34. (original) The method of claim 1, further comprising administering a visualizing agent to the subject.

C 1

35. (original) The method of claim 1, wherein the electrodes comprise meander electrodes.

Cont

36. (currently amended) A method for treating a cell proliferative disorder in a subject comprising:

(a) administering ~~a photooxidizing agent~~ to a subject having or suspected of having a proliferative disorder a pharmaceutically acceptable formulation consisting essentially of a photosensitive agent that is a photosensitive agent or (ii) a plurality of different photosensitive agent species, wherein at least one of the photosensitive agent species

Jan 06 04 05:28a Biotechnology Law Group 18583509891 p.5

PAGE 6/13 * RCVD AT 1/8/2004 12:27:23 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729305 * CSID:18583509691 * DURATION (mm-ss):06-08

is a photooxidizing agent;

(b) applying an electric pulse to the cell in the subject of a sufficient strength and duration to electroporate the cell with the ~~photooxidizing~~ photosensitive agent(s); and

(c) applying light of a photoactivating wavelength to the cell thereby photoactivating the agent(s) and treating the cell proliferative disorder.

37. (original) The method of claim 36, wherein the cell proliferative disorder is benign.

38. (original) The method of claim 36, wherein the cell proliferative disorder is a cancer.

39. (original) The method of claim 38, wherein the cancer is selected from the group consisting of skin cancer, a solid tumor, a metastasizing cancer and hematopoietic cancer.

40. (original) The method of claim 39, wherein the hematopoietic cancer is histiocytic lymphoma.

41. (canceled)

42. (original) The method of claim 36, wherein the electric pulse's amplitude is about 10 V/cm to 6.0 kV/cm.

C 1

43. (canceled)

Cont

44. (original) The method of claim 36, wherein the pulse is applied using at least two electrodes.

45. (original) The method of claim 36, wherein at least one light conductor is combined with the electrode.

Jan 06 04 05:28a Biotechnology Law Group 18583509691 p.6

PAGE 7/13 * RCVD AT 1/6/2004 12:27:23 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729305 * CSID:18583509891 * DURATION (mm-ss):06-08

46-51. (canceled)

52. (original) The method of claim 36, wherein the light is applied prior to, simultaneously with, or following the pulse.

53. (original) The method of claim 36, wherein the light is applied by a laser.

54. (original) The method of claim 36, wherein the light is applied by a tungsten lamp.

55. (original) The method of claim 36, wherein the light is applied by a near ultraviolet lamp.

56. (original) The method of claim 36, wherein the light has a wavelength of about 300 to about 950 nm.

57. (original) The method of claim 36, wherein the amount of light applied is about 50 to about 1000J/cm^2.

58-61. (canceled)

C 1

62. (original) The method of claim 36, further comprising applying heat to the cell.

63. (currently amended) The method of claim 62, wherein the heat has a temperature of about 36°C to about 42°C.

Cont

64. (canceled)

Jan 06 04 05:28a Biotechnology Law Group 18583509891 p.7

PAGE 8/13 * RCVD AT 1/6/2004 12:27:23 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/1 * DNIS:8729305 * CSID:18583509691 * DURATION (mm-ss):06-08

65. (original) The method of claim 64, wherein the photooxidizing agent is selected from the group consisting of thiopyronin, acridine orange, Zn-phthalocyanine-sulfonate, benzoporphyrin, protoporphyrin, ~~hematoporphyrin.~~ PHOTOFRIN I, PHOTOFRIN II, ANTRIN and porphycene.

66. (original) The method of claim 36, wherein the photosensitive agent is a cytostatic agent.

67. (original) The method of claim 66, wherein the cytostatic agent is selected from the group consisting of daunomycin, adriamycin and actinomycin.

C 1 Cont

68. (original) The method of claim 36, further comprising providing a sensitizing agent.

69-79. (canceled)

Jan 06 04 05:28a Biotechnology Law Group 18583509691 p.8